Guggenheim Cuts Price Target on Tetraphase Pharma (TTPH) Following Disappointing cUTI Data.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks gain, oil prices slide
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Tetraphase Announces Top-Line Results From IGNITE2 Phase 3 Clinical Trial of Eravacycline in cUTI
September 8, 2015 4:01 PM EDTEravacycline Did Not Achieve Primary Endpoint in Pivotal Portion of cUTI Trial
Company to Host Conference Call at 4:30 p.m. ET Today
WATERTOWN, Mass., Sept. 8, 2015 (GLOBE NEWSWIRE) --... More
Tetraphase Announces Top-Line Results From IGNITE2 Phase 3 Clinical Trial of Eravacycline in cUTI
September 8, 2015 4:01 PM EDTEravacycline Did Not Achieve Primary Endpoint in Pivotal Portion of cUTI Trial
Company to Host Conference Call at 4:30 p.m. ET Today
WATERTOWN, Mass., Sept. 8, 2015 (GLOBE NEWSWIRE) --... More
